Harmony Biosciences Holdings, Inc. (HRMY) vs. Broadcom Inc. (AVGO) Stock Comparison & Valuation | Edwyn

Edwyn

Edwyn Search companies, tickers, CIKs…⌘K

Harmony Biosciences Holdings, Inc. (HRMY) vs. Broadcom Inc. (AVGO) Stock Comparison & Valuation | Edwyn

Updated 2026-07-03 16:12 UTC

This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.

HRMY screens as materially undervalued versus a high-growth AVGO framework, with its current price far closer to historical/DCF ranges than to the AVGO-based implied valuation, while still showing solid profitability and a very strong balance sheet.

Actionable Takeaway

If you believe HRMY can sustain its 21.5% revenue growth while maintaining current profitability and balance-sheet strength, then the current price looks more attractive than the AVGO-implied valuation because HRMY already trades near its historical and DCF ranges rather than AVGO-multiple estimate.

HRMY trades at $37.28 versus a P/E-implied value of $131.72, implying 253.3% upside, but AVGO-based valuation appears heavily skewed by AVGO’s much larger scale and different business model. The more decision-relevant anchors are HRMY’s historical band of $33.55-$41.01 and DCF range of $33.52-$45.35, both of which bracket the current price closely.

Supporting Metrics

Key Risks

HRMY’s Piotroski F-Score of 5/9 suggests the fundamental picture is only middling, not uniformly strong.
AVGO comparison to AVGO may overstate upside because AVGO’s 48.6x P/E and 26.8x P/S reflect a very different scale and business profile.
HRMY’s operating margin of 24.0% and net margin of 18.3% are meaningfully below AVGO’s 39.9% and 36.2%, which could limit rerating potential.